English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Astrazeneca
Press release submission
| Sep 16, 2018
ASTRAZENECA: US FDA approves LUMOXITI™ (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukemia
Marian Johns
| Jan 17, 2018
FDA approves Lynparza as first PARP Inhibitor for treating metastatic breast cancer
Trending
+
Pharmaceuticals
Patient Daily
| Jun 2, 2025
PathAI collaborates with Northwestern Medicine on digital pathology advancements
+
Regulatory
Patient Daily
| May 30, 2025
Alliance for Pharmacy Compounding calls for eliminating redundant, unauthorized, or ineffective regulation
+
Pharmaceuticals
Patient Daily
| Jun 5, 2025
Exon 20 Group questions effectiveness of 340B drug program
+
Pharmaceuticals
Patient Daily
| Jun 5, 2025
New study identifies indicators for HER2+ breast cancer therapy response
